ReleaseWire

Macular edema results from fluid accumulation in the macular region of the retina. Macular edema arises from various etiologies such as diabetes, AMD, and RVO. Macular edema disrupts the central vision due to swelling of the macula. Currently, the treatment plan involves the use of surgical and laser therapies as well as drugs such as anti-VEGF therapies and NSAIDs. Surgery and laser therapy are intended to prevent further damage to vision. However, anti-VEGF therapies have been reported to improve the vision loss associated with macular edema.

GlobalData's clinical trial report, "Paraplegia Global Clinical Trials Review, H1, 2014 provides data on the Paraplegia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Paraplegia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Paraplegia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Hypersomnia Global Clinical Trials Review, H1, 2014 provides data on the Hypersomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypersomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hypersomnia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates". It is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in the UAE, identifying key trends in its healthcare market and providing insights into its demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical devices market, using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Batten Disease - Pipeline Review, H2 2014', provides an overview of the Batten Disease's therapeutic pipeline.

Global Markets Direct's, 'Virobay Inc. - Product Pipeline Review - 2014', provides an overview of the Virobay Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Amura Holdings Ltd. - Product Pipeline Review - 2014', provides an overview of the Amura Holdings Ltd.'s pharmaceutical research and development focus.

The Hansen Medical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Hansen Medical, Inc. since January 2007.

Global Markets Direct's, 'Immupharma Plc - Product Pipeline Review - 2014', provides an overview of the Immupharma Plc's pharmaceutical research and development focus.

Global Markets Direct's, 'Euroscreen S.A. - Product Pipeline Review - 2014', provides an overview of the Euroscreen S.A.'s pharmaceutical research and development focus.

Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. CF patients have a limited number of available treatment options and significant unmet needs still exist. Opportunities are significant for new therapies that will improve symptoms, change the course of this disease, as well as increase therapy options. The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex in 2012, paved the way for a new class of therapies known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. On June 24, 2014, Vertex announced positive Phase III clinical trial data for lumacaftor in combination with Kalydeco in patients with CF who have two copies of the F508del mutation. This novel combination therapy of CFTR modulators has the potential to treat the underlying cause of the disease for approximately 50% of all CF patients and drive rapid growth in the CF market.

Global Markets Direct's, 'Chronic Heart Failure - Pipeline Review, H2 2014', provides an overview of the Chronic Heart Failure's therapeutic pipeline.

GBI Research, the leading business intelligence provider, has released its latest research: "Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market", which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

Global Markets Direct's, 'Aestus Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Aestus Therapeutics, Inc.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Intracranial Hypertension Global Clinical Trials Review, H2, 2014 provides data on the Intracranial Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Intracranial Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Intracranial Hypertension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Can-Fite BioPharma Ltd, a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health (MOH) has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. Food and Drug Administration for CF102 in the treatment of advanced hepatocellular carcinoma.

GlobalData's clinical trial report, "Myoclonic Seizures Global Clinical Trials Review, H2, 2014 provides data on the Myoclonic Seizures clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Myoclonic Seizures. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Myoclonic Seizures. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H2 2014', provides an overview of the Follicular Lymphoma's therapeutic pipeline.

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person's symptoms, changes in the ST-tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

Global Markets Direct's, 'Neurofibromatoses Type II - Pipeline Review, H2 2014', provides an overview of the Neurofibromatoses Type II's therapeutic pipeline.

Global Markets Direct's, 'Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2014', provides an overview of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C's therapeutic pipeline.

Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2014', provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)'s therapeutic pipeline.

Global Markets Direct's, 'Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H2 2014', provides an overview of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)'s therapeutic pipeline.

GlobalData's clinical trial report, "Encephalomyelitis Global Clinical Trials Review, H1, 2014 provides data on the Encephalomyelitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Encephalomyelitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Encephalomyelitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Brain Tumor - Pipeline Review, H2 2014', provides an overview of the Brain Tumor's therapeutic pipeline.